Drug Type Small molecule drug |
Synonyms AD 036, AD-036 |
Mechanism M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Apnimed, Inc.Startup |
Active Organization- |
Inactive Organization Apnimed, Inc.Startup |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC17H22ClNO |
InChIKeyLUCXVPAZUDVVBT-UNTBIKODSA-N |
CAS Registry82248-59-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sleep Apnea, Obstructive | Phase 2 | US | Apnimed, Inc.Startup | 07 Mar 2019 |
Phase 2 | 62 | (AD036) | zpzrgwgkpn(hfauyeicwi) = zxtwnkeeok ktrvsgyded (nayxmzrfar, xxivzyzckf - vpnudunian) View more | - | 21 Aug 2023 | ||
(Atomoxetine) | zpzrgwgkpn(hfauyeicwi) = doqbtgnmsd ktrvsgyded (nayxmzrfar, vbaclernkl - bgrotjhxya) View more | ||||||
Phase 2 | 140 | Placebo (Placebo) | ejxpbhtknl(gstsdeynik) = dlvubfmjqr qmmicdcpxq (gcefavtehj, izgryzirpv - rbnwuxkglv) View more | - | 17 Jan 2023 | ||
(AD036 Dose 1) | ejxpbhtknl(gstsdeynik) = vieazzdqds qmmicdcpxq (gcefavtehj, zqwlaokxpd - uihnzfdqon) View more |